1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M


1 Year 1Y

5 Years 5Y

About Bristol-Myers Squibb Co.

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
Giovanni Caforio

430 E 29th St Fl 14
New York, New York 10016-8367
Phone: 12125464000


Drugmakers Agree To Participate For Medicare Drug Price Negotiation With Biden Administration
Oct 03, 2023 17:35pm

All ten manufacturers of the first drugs selected for Medicare price negotiations will be participating, the White House said, even though many of them are suing the administration to halt the process . Last year, about 9 million Medicare enrollees spent $3.4 billion out of pocket on the selected drugs from companies, including Johnson & Johnson (NYSE: JNJ ), Merck & Co Inc (NYSE: MRK ), Bristol Myers Squibb Co (NYSE: BMY ), and AstraZeneca Plc (NASDAQ: Full story available on

Cancer Drug Approval? 3 Biotech Stocks on the Brink of Breakthroughs
Oct 02, 2023 23:09pm

Autologous chimeric antigen receptor T cell therapy is 0ne of the most promising, relatively new types of cancer treatments. CAR T involves “reprogramming” patients’ T cells, which fight hostile cells within the body. Specifically, CAR T treatments work by reconfiguring T cells so that they attack proteins found on tumors. CAR T also attacks other cells altered by tumors. One reason this type of therapy is so promising is that it produces treatments that work well within each patients’ body. That’s because the treatments are specifically tailored to each patients’ T cells. This revolutionary techology has brought up some of the best cancer drug stocks we have ever seen. Moreover, unlike other cancer treatments, CAR T drugs enlist cells that come from the patients themselves in the cancer-fighting effort. In other words, CAR T produces treatments that are “personalized” to each patient. Finally, “ After a one-time infusion, the CAR T cells can continue to multiply in the patient’s body after being administered ,” Bristol-Myers Squibb (NYSE: BMY ) explained.

Bristol-Myers Squibb: How Cheap Is Cheap Enough?
Sep 28, 2023 18:00pm

BMY faces a significant decline in sales due to loss of exclusivity for Revlimid, impacting stock valuations and lowering guidance for FY2023. Read here for more.

Source:Seeking Alpha
Bristol-Myers: Out Of Favor (Rating Upgrade)
Sep 28, 2023 18:00pm

Bristol-Myers Squibb stock has hit a new low and is currently out of favor in the market. Check out why I''m bullish on BMY stock right now.

Source:Seeking Alpha
Bristol-Myers Squibb Unusual Options Activity For September 27
Sep 27, 2023 20:16pm

Someone with a lot of money to spend has taken a bullish stance on Bristol-Myers Squibb (NYSE: BMY ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don''t know. But when something this big happens with BMY, it often means somebody knows something is about to happen. So how do we know what this whale just did? Today, Benzinga ''s options scanner spotted 10 uncommon options trades for Bristol-Myers Squibb. This isn''t normal. The overall sentiment of these big-money traders is split between 70% bullish and 30%, bearish. Out of all of the special options we uncovered, 5 are puts, for a total amount of $155,031, and 5 … Full story available on

Bristol-Myers Squibb Looks Grossly Overvalued With LOE Taking A Bite Out Of Topline
Sep 27, 2023 10:09am

Bristol-Myers Squibb stock appears cheap with a low P/E ratio, but its sales are expected to decline due to patent expirations. Learn why I see BMY as grossly overvalued.

Source:Seeking Alpha
Fortem Financial Group LLC Boosts Holdings in Bristol-Myers Squibb (NYSE:BMY)
Sep 26, 2023 20:29pm

… during the period. Fortem Financial Group LLC’s holdings in … the last quarter. Catalyst Financial Partners LLC lifted its position … the first quarter. Catalyst Financial Partners LLC now owns 6 … Friday, September 15th. Truist Financial restated a “buy” rating …

Source:EIN News Finance
Bristol Myers Squibb to Report Results for Third Quarter 2023 on October 26, 2023
Sep 26, 2023 10:59am

Bristol Myers Squibb (NYSE: BMY) will announce results for the third quarter of 2023 on Thursday, October 26, 2023. Company executives will review financial results and address inquiries from investors and analysts during a conference call beginning at 8:00 a.m. ET on the same date. Investors and the general public are invited to listen to a live webcast of the call at

Bristol Myers Squibb: Undervalued Already, But Could Go Lower
Sep 26, 2023 09:56am

Although Bristol Myers Squibb is struggling to grow, its new product portfolio is promising. Click here to see why BMY stock is undervalued.

Source:Seeking Alpha
Bristol Myers Squibb: Close To Fair Value, Headwinds For Next Few Years
Sep 26, 2023 07:33am

Bristol Myers Squibb''s defensive strategy to defend the value of its legacy products may not be successful. Check out why I''m neutral on BMY stock.

Source:Seeking Alpha